Skip to main content
MDXG logo

MDXG · Mimedx Group, Inc.

Track MDXG — free
$3.05 -0.06 (-1.94%)
Market Cap
$453.83M
Shares
145.93M
Volume · Nov 19 2.02M Avg daily vol (3M) 1.37M

Price & Indicators

 

Key stats

Close
$3.11
Open
$3.18
Day range
$3.07–3.28
52-week closing range
$3.09–7.25
Average volume, 30 days
1.7M
Short interest
9.0M · 6.1% of shares · 4.4 days
Short volume, last session
50%
Last earnings
Oct 28, 2026
Latest filing
10-Q · Oct 28
Price history
Jan 2020 to Nov 2026

Up next

Feb 24, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Oct 28
Earnings call
Net Sales Fall 45% to $62 Million; FTC Delays Scenera Deal

MyMedx reported third-quarter 2026 net sales of $62 million, down 45% from the prior year period. Surgical sales rose 9% to $40 million, while wound sales fell 71% to $22 million. The FTC issued a second request that extends the Hart-Scott-Rodino waiting period for the pending Scenera MedTech acquisition.

4 source passages
third quarter 2026 net sales were $62 million, down 45% from the prior year period. surgical net sales of $40 million grew 9% year-over-year and 2% sequentially during the third quarter. Wound net sales were $22 million, down 71% from the prior year period. the FTC has issued a second request for information, which extends the Hart-Scott-Rodino waiting period. Open the document at this passage
Oct 28
Current report 8-K
Third-quarter net sales fall 45% to $62 million

MiMedx reported third-quarter 2026 net sales of $62 million, compared to $114 million for the three months ended September 30, 2025, a decrease of 45%. It swung to a net loss of $9 million from net income of $17 million a year earlier. For 2026 it expects net sales of $250 to $260 million, and a patent license will pay $25 million in five installments.

Financial results, Regulation FD disclosure Read from the first part of this long document
4 source passages
MIMEDX reported net sales for the three months ended September 30, 2026 of $62 million, compared to $114 million for the three months ended September 30, 2025, a decrease of 45%. Net loss for the three months ended September 30, 2026 was $9 million compared to net income of $17 million for the three months ended September 30, 2025. For 2026, MIMEDX now expects 2026 net sales to be in a range of $250 to $260 million. The licensee will pay MIMEDX a total of $25 million in five equal installments of $5 million. Open the document at this passage
Oct 28
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Net sales fell 45.2% as Wound sales dropped 71.0%

Net sales were $62.3 million for the three months ended September 30, 2026, a decrease of 45.2%, with Wound sales down 71.0% on Medicare reimbursement changes. The company reported a GAAP net loss of $9 million, or $0.06 per diluted share. On October 15, 2026, the company and Sanara each received an FTC Second Request, extending the HSR waiting period for the pending acquisition.

Revenue $62.28M ▼ 45.2% Net loss $8.68M Diluted EPS -$0.06
Read from the MD&A section
6 source passages
Net sales were $62.3 million for the three months ended September 30, 2026, representing a decrease of $51.4 million, or 45.2% Wound net sales were $22.3 million for the three months ended September 30, 2026, representing a decrease of $54.8 million or 71.0% This decrease was primarily driven by the continued impact of Medicare reimbursement changes effective January 1, 2026 We reported a GAAP net loss of $9 million or $0.06 per diluted share On October 15, 2026, we and Sanara each received a request for additional information (the “Second Request”) and documentary materials from the Federal Trade Commission (“FTC”) The effect of the Second Request is to extend the waiting period imposed by HSR until 30 days after the parties have substantially complied with the Second Request Open the document at this passage
Oct 16
Current report 8-K Events of Oct 15
Other events

MiMedx Group, Inc. and Sanara MedTech Inc. each received a Second Request from the Federal Trade Commission on October 15, 2026 in connection with the FTC's review of their pending merger, extending the HSR Act waiting period.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$303.73M
Trailing 12 months
Net income (TTM)
−$19.19M
Trailing 12 months
Revenue growth YoY
-45.2%
Year over year
Operating margin
-8.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$120.79M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-2.6%
Year over year · fewer shares
Price change (1Y)
-52.0%
Trailing year
Short interest
6.1%
Latest settlement · 4.4 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Jul 29, 2026
Q2 FY26

TL;DR. MIMEDX reported Q2 net sales of $64 million, down 35% year-over-year on Medicare reimbursement headwinds in Wound, but delivered 9% sequential growth, 15% Surgical growth, and a $300 million-funded acquisition of Sanara MedTech that targets combined 2027 revenue above $400 million and adjusted EBITDA margin above 20%.

Bullish
  • + Surgical revenue grew 15% year-over-year in Q2 2026
  • + Sequential revenue grew 9% with each month improving and June at $24 million
  • + Wound care center unit volume grew 44% sequentially and 22% overall sequentially
  • + Announced acquisition of Sanara MedTech with expected combined 2027 revenue well in excess of $400 million and adjusted EBITDA margin above 20%
  • + Secured committed $300 million term loan financing for the Sanara acquisition
  • + Submitted first two 510(k) applications, expanding regulatory pathway for placental and antimicrobial products
Bearish
  • − Q2 net sales declined 35% year-over-year due to Medicare reimbursement changes
  • − Wound sales fell 61% year-over-year to $25 million
  • − GAAP net loss of $15 million versus $10 million net income in the prior-year quarter
  • − Adjusted EBITDA was a loss of $8 million (negative 13% margin) versus positive $24 million a year ago
  • − Gross margin contracted to 69% from 81% on Wound pricing pressure
  • − CMS proposed 2027 physician fee schedule indicates the current $127.14/sq. cm. skin substitute rate will remain, prolonging reimbursement pressure

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −25%
below
Price vs 50-day avg −25%
below
RSI (14) 23
oversold
MACD trend Positive
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −21%
trailing
6-month return −13%
trailing
YTD return −54%
this year
Relative strength −8%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow Distributing
-4% holders QoQ · +27 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
6.15% of shares out · ▼ -3.2% MoM · 4.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
219 holders — mid 3-yr range
Squeeze score 60
elevated · 0–100
Fundamentals
Excellent
Revenue growth +20%
Y/Y
Gross margin 83%
contracting
EPS growth +14%
Y/Y
Free cash flow $72.0M
Buyback $100.0M
authorized
Balance sheet $148.2M
net cash
Quant / Vol
risk profile
Very High
Volatility 43%
annualized · 1-yr
Max drawdown −57%
past year
ATR 6.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 2 of last 2
Latest guidance · from the 8-K filed Oct 28, 2026
For 2026
2026 net sales Lowered $250M – $260M
Jul 29, 2026 $260M – $290M changed to Oct 28, 2026 $250M – $260M
prior FY $418.63M midpoint −39.1% Y/Y
In the first full year post-close
Total revenue $400M
Adj. EBITDA margin Non-GAAP at least 20%
to be realized in 2027
Annualized, run-rate cost synergies at least $20M
Previous outlook earlier release · from the 8-K filed Jul 29, 2026

Still-open targets the latest release did not restate under the same label.

Adjusted EBITDA margin · Longer-term at least 20%
Adj. EBITDA margin · first full year post-close at least 20%
Total revenue · In the first full year post-close at least $400M
Annualized, run-rate cost synergies · to be realized in 2027 at least $20M
Adj. EBITDA margin · In the first full year post-close at least 20%
Guided vs delivered · last 2 settled
Net sales fourth quarter 2022
guided $73M – $76M
$74.38M In line
Net sales full year 2022
guided $266M – $269M
$267.84M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−25% Bearish
Price vs 50-day avg
−25% Bearish
RSI (14)
23 Neutral
MACD trend
Positive Bullish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow Distributing
-4% holders QoQ · +27 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
6.15% of shares out · ▼ -3.2% MoM · 4.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
219 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3 Now $3 · 0% Range high $7
vs 200-day avg -25% vs 50-day avg -25%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MDXG
Mimedx Group, Inc.
this stock
$453.83M -54.1% +20.0% — 6.1%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
219
% held
79.7%
Net QoQ
+4.4M sh
Top holder
Essex Woodlands Managemen…
Held Float
View
Held by Funds
Fund positions
172
View
Short & Settlement
Short Interest Falling
Shares short
9.0M
Days to cover
4.4d
Change
-296.9K sh
View
Short Volume
Short vol %
50%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
1.5K
Value
$7.0K
As of
Oct 14, 2026
View
Off-Exchange
Off-exchange %
41.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$418.6M
Net income (FY)
$48.6M
EPS diluted
$0.32
View
Buybacks
Authorized
$100.0M
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 28, 2026
This year
18

MiMedx reported third-quarter 2026 net sales of $62 million, compared to $114 million for the three months ended September 30, 2025, a decrease of 45%. It swung to a net loss of $9 million from net income of $17 million a year earlier. For 2026 it expects net sales of $250 to $260 million, and a patent license will pay $25 million in five installments.

View
Proposed Sales
Value
$646.7K
Shares
81.4K
Filed
Mar 10, 2025
View
Earnings & Events
Webcasts
Last webcast
Oct 28, 2026
View
Investor Relations
Latest news
MIMEDX to Participate in Upcoming…
Published
Nov 6, 2026
View

Performance

5D 20D 120D MTD YTD
MDXG -4.0% -20.9% -13.1% -19.9% -54.1%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +1.4% -14.6% -7.5% -14.6% -59.0%

Capital returns

Buyback program · as of Feb 28, 2026
Authorized
$100.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1376339 CUSIP 602496101 13F (30d) 216 filings 198 filers Visit website Investor relations